The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE).
SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE).
Investors who purchased Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) shares prior to December 2020 and continue to hold any of their Ampio Pharmaceuticals, Inc. shares have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On November 29, 2022, a lawsuit was filed against Ampio Pharmaceuticals, Inc. over alleged Securities Laws Violations. The plaintiff alleged that the defendants, inflated the Company’s true ability to successfully file a Biologics License Application for Ampion, inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study, and that as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) shares should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
